Stempoint Capital’s RAPT Therapeutics RAPT Stock Holding History

Stempoint Capital’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,306	Closed	-$1.45M	–	91
2023 Q4	$1.45M	Buy	+7,306	New	+$904K	0.39%	53

Other funds holding RAPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Stempoint Capital's RAPT Position: Q1 2024 in Review

Stempoint Capital sold out of RAPT Therapeutics (RAPT) in Q1 2024, closing a stake of 7,306 shares — an estimated $1.45M sold.

Stempoint Capital first reported a position in RAPT in Q4 2023 and held it in 1 quarter. The position peaked at $1.45M in Q4 2023. 121 funds tracked by Wall St. Rank hold RAPT as of Q1 2024.

Stempoint Capital reported no remaining RAPT Therapeutics position as of Q1 2024 after selling out during the quarter.
Stempoint Capital sold 7,306 RAPT Therapeutics shares in Q1 2024, an estimated $1.45M.
Stempoint Capital first reported a position in RAPT Therapeutics in Q4 2023 and held it in 1 quarter.
Stempoint Capital's RAPT Therapeutics position peaked at $1.45M in Q4 2023.
121 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2024.

Based on Stempoint Capital's 13F filing for Q1 2024, filed 14 May 2024.